Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19
Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · Apr 9, 2020
Trial Information
Current as of May 08, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • confirmed COVID-19 disease
- • refractory shock with need for norepinephrine ≥ 0.2 μg/kg/min for MAP ≥ 65 mmHg
- • IL6 ≥ 500 ng/l
- • Indication for CRRT or ECMO
- Exclusion Criteria:
- • Liver cirrhosis Child Pugh C
- • "do not resuscitate"-order
- • expected survival due to comorbidities \< 14 days
- • pregnancy or breastfeeding
- • participation in another interventional trial
About Universitätsklinikum Hamburg Eppendorf
Universitätsklinikum Hamburg-Eppendorf (UKE) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, UKE integrates state-of-the-art facilities with a multidisciplinary approach, fostering collaboration among top-tier researchers, clinicians, and healthcare professionals. The institution is dedicated to improving patient outcomes by conducting rigorous scientific investigations that address critical health challenges, ultimately contributing to the development of novel therapies and enhancing medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamburg, , Germany
Patients applied
Trial Officials
Stefan Kluge, MD
Principal Investigator
University Hospital Hamburg-Eppendorf, Department of Intensive Care Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials